Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.
source https://www.pharmatutor.org/pharma-news/2020/fda-approves-bavencio-as-treatment-for-metastatic-urothelial-carcinoma
No comments:
Post a Comment